Frequency-dependent selection in human immunodeficiency virus type 1

Selection of T1249-resistant human immunodeficiency virus type 1 variants.

Human immunodeficiency virus type 1 (HIV-1) entry is an attractive target for therapeutic intervention. Two drugs that inhibit this process have been approved: the fusion inhibitor T20 (enfuvirtide [Fuzeon]) and, more recently, the CCR5 blocker maraviroc (Selzentry). T1249 is a second-generation fusion inhibitor with improved antiviral potency compared to the first-generation peptide T20. We se...

Resistance mechanism of human immunodeficiency virus type-1 protease to inhibitors: A molecular dynamic approach

Human immunodeficiency virus type 1 (HIV-1) protease inhibitors comprise an important class of drugs used in HIV treatments. However, mutations of protease genes accelerated by low fidelity of reverse transcriptase yield drug resistant mutants of reduced affinities for the inhibitors. This problem is considered to be a serious barrier against HIV treatment for the foreseeable future. In this st...

Quantification Analysis of Dot Blot Assays for Human Immunodeficiency Virus Type 1 and 2 Antibodies

Objective Dot Blot (DB) assay provides highly specific results, but usually not reliable for quantification of antibody production. The need for a more objective DB assay to provide a better definition of the immune status, against HIV antigens, promoted this study to be done to develop a quantitative DB assay. Material and Methods Dot blot (DB) strips for antibodies directed to human immuno...

Evaluating the Frequency of Human T-Lymphotropic Virus Type 1 Infection in Iranian Population

Background: Human T-cell lymphotropic viruses 1 (HTLV1) is endemic in specific regions. We aimed to determine the prevalence of HTLV I infection among blood donors in southeast Iran.   Methods: This cross-sectional study was conducted between April 2005 and March 2015. Sera were collected from blood donors and were tested for the presence of HTLV1 specific antibody using ELISA. Reactive sample...

human immunodeficiency virus type 1 Tat